Company intelligence
Parker Institute for Cancer Immunotherapy
Our mission is to accelerate the development of breakthrough immune therapies to turn all cancers into curable diseases
About Parker Institute for Cancer Immunotherapy
For decades, entrenched infrastructure barriers have slowed progress in the fight against cancer and the development of potent immunotherapies. The Parker Institute for Cancer Immunotherapy breaks down these barriers. The result is groundbreaking new research and an intellectual property model that builds collaboration between researchers, nonprofits and industry all working together to get treatments to patients faster.
Verified activity
Signals from Parker Institute for Cancer Immunotherapy
4 published signals
Research & Knowledge
Parker Institute for Cancer Immunotherapy reported that Dispatch Bio has dosed its first patient in a Phase 1 clinical trial of DISP-10, a novel approach to treating solid tumors.
Reported by Parker Institute for Cancer Immunotherapy
Research & Knowledge
Parker Institute for Cancer Immunotherapy researcher Xinyu Xiang is developing a new platform to generate T cell receptor mimetics that recognize tumor-associated peptide-MHC complexes with high specificity.
Reported by Parker Institute for Cancer Immunotherapy
Research & Knowledge
Parker Institute for Cancer Immunotherapy awarded Parker Scholar Xinyu Xiang at Stanford University School of Medicine.
Reported by Parker Institute for Cancer Immunotherapy